-

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023, and will participate in one-on-one meetings with investors throughout the day, in New York, NY.

Presentation Details:
Date: Tuesday, November 28, 2023
Time: 10:10 a.m.-10:30 a.m. EST
Location: Lotte New York Palace, 455 Madison Ave, New York, NY 10022

About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company has now initiated three Phase 2 clinical programs in hepatocellular carcinoma (NCT05440708), metastatic breast cancer (NCT05384119), and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit the website for Tvardi Therapeutics.

Contacts

Tvardi Investor Relations
Sara Manning
ir@tvardi.com

Industry:

Tvardi Therapeutics, Inc.

Release Versions
English
Hashtags
#BreastCancer
#HCC
#HepatocellularCarcinoma
#IdiopathicPulmonaryFibrosis

Contacts

Tvardi Investor Relations
Sara Manning
ir@tvardi.com

Social Media Profiles
Tvardi LinkedIn
Tvardi Twitter
More News From Tvardi Therapeutics, Inc.

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company’s management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Pi...

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipat...

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference. The Jeffer...
Back to Newsroom